Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer

Volumn 15, Issue 2, 2017, Pages e217-e222

  Miyake, Hideaki ^a,b   Hara, Takuto ^a   Ozono, Seiichiro ^b   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abiraterone acetate; Cross resistance; Docetaxel; Enzalutamide; Progression free survival

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHRONOPHARMACOLOGY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FUNCTIONAL STATUS ASSESSMENT; GLEASON SCORE; HUMAN; INDEPENDENT VARIABLE; JAPANESE (PEOPLE); LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL METASTASIS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84994218021     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.07.005     Document Type: Article

References (25)

1. 1 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50 (2014), 1617–1627.
3. 3 Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
4. 4 Petrylak, D.P., Tangen, C.M., Hussain, M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004), 1513–1520.
5. 5 Chi, K., Hotte, S.J., Joshua, A.M., et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26 (2015), 2044–2056.
6. 6 Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
7. 7 Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
8. 8 Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
9. 9 Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
10. 10 Francini, E., Petrioli, R., Roviello, G., No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 14 (2014), 1135–1140.
11. 11 Lebdai, S., Basset, V., Branchereau, J., et al. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. World J Urol 34 (2016), 617–624.
12. 12 Bianchini, D., Lorente, D., Rodriguez-Vida, A., et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50 (2014), 78–84.
13. 13 Badrising, S., van der Noort, V., van Oort, I.M., et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120 (2013), 968–975.
14. 14 Loriot, Y., Bianchini, D., Ileana, E., et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24 (2013), 1807–1812.
15. 15 Noonan, K.L., North, S., Bitting, R.L., et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24 (2013), 1802–1807.
16. 16 Cheng, H.H., Gulati, R., Azad, A., et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 18 (2015), 122–127.
17. 17 Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
18. 18 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
19. 19 de Bono, J.S., Oudard, S., Ozguroglu, M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
20. 20 van Soest, R.J., Nieuweboer, A.J., de Morrée, E.S., et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer 51 (2015), 2562–2569.
21. 21 Ciccarese, C., Santoni, M., Brunelli, M., et al. AR-V7 and prostate cancer: The watershed for treatment selection?. Cancer Treat Rev 43 (2016), 27–35.
22. 22 Buttigliero, C., Tucci, M., Bertaglia, V., et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41 (2015), 884–892.
23. 23 Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
24. 24 Nakazawa, M., Lu, C., Chen, Y., et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 26 (2015), 1859–1865.
25. 25 Azad, A.A., Eigl, B.J., Murray, R.N., et al. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 67 (2015), 23–29.